Minerva Neurosciences (NERV) Equity Ratio (2013 - 2026)

Minerva Neurosciences has reported Equity Ratio for 14 years, with the latest figure at 2.7 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 203.97% year-over-year to 2.7; the trailing twelve-month figure through Mar 2026 stood at 2.7 (down 203.97% YoY), and the FY2025 full-year result was 1.44, down 107.69% from the prior year.
• Equity Ratio for Q1 2026 stood at 2.7, down from 1.44 in the prior quarter.
• The five-year high for Equity Ratio was 0.01 in Q1 2022, with the low at 2.7 in Q1 2026.
• Historically, Equity Ratio has averaged 0.73 across 5 years, with a median of 0.52 in 2023.
• Annual changes were most pronounced in 2023 — Equity Ratio sank 4849.16% — and 2025, when it retreated 9.82%.
• Minerva Neurosciences' Equity Ratio stood at 0.36 in 2022, then sank by 37.59% to 0.5 in 2023, then plunged by 38.31% to 0.69 in 2024, then plunged by 107.69% to 1.44 in 2025, then slumped by 88.04% to 2.7 in 2026.
• The last three Equity Ratio figures came in at 2.7 (Q1 2026), 1.44 (Q4 2025), and 1.23 (Q3 2025), per Business Quant data.